Almirall takes option on Dermira’s eczema drug lebrikizumab

Spain’s Almirall has taken an option granting rights to develop and market Dermira’s eczema drug lebrikizumab in Europe, in a bid to take on Sanofi/Regeneron’s recently approved Dupixent. The companies had struck an option and license agreement in February which granted Almirall European rights to the drug in atopic dermatitis, also known as eczema, and certain other indications.
Read more...

;